Key Highlights

  • XGN closed up 35% at $3.98 — one of the session's most decisive moves
  • Record Q1 2026 Revenue of $17.3 million, up 12% year-over-year
  • AVISE CTD testing Volume continues to grow, driven by rheumatology adoption
  • Higher average selling prices contributing to improved revenue quality
  • Adjusted EBITDA trajectory improving quarter on quarter
  • Full-year 2026 revenue guidance reaffirmed at $70–$73 million

 

Exagen Inc. (Nasdaq: XGN) surged 35 per cent to close at $3.98 on Tuesday after the medical diagnostics company reported a first quarter that exceeded expectations on the metrics that matter most for a diagnostics Business at this stage of its commercial development: volume, pricing, and the trajectory toward profitability. The combination of record revenue, improving adjusted EBITDA, and maintained annual guidance was sufficient to catalyse a re-rating that, while dramatic in percentage terms, reflects the market catching up to an operational story that has been building quietly for several quarters.

First-quarter revenue of $17.3 million represented a 12 per cent increase over the prior year period, driven by continued growth in AVISE CTD testing volume and higher average selling prices. AVISE CTD — the company's proprietary multi-biomarker test for the evaluation of connective tissue diseases including systemic lupus erythematosus — is the Franchise asset around which Exagen has built its commercial infrastructure and clinical differentiation narrative.

Connective tissue disease diagnosis is notoriously challenging. Systemic lupus erythematosus in particular is a disease of protean clinical manifestations that frequently mimics other conditions, leading to an average diagnostic delay of several years. AVISE CTD's multi-biomarker approach — incorporating anti-dsDNA antibodies, cell-bound complement activation products, and other markers — provides a more complete biological picture than individual tests alone, supporting earlier and more accurate diagnosis and enabling more targeted treatment decisions.

The higher average selling prices achieved in the quarter reflect both favourable payor mix and Exagen's ongoing efforts to expand reimbursement coverage and negotiate improved contract terms. Sustainable commercial expansion in diagnostics requires both volume and price to move in concert. The simultaneous improvement in both metrics in Q1 suggests effective execution across commercial and managed care operations.

The improving adjusted EBITDA performance is the figure that most meaningfully changes the Investment narrative. A diagnostics company growing revenue at double-digit rates while simultaneously moving toward profitability is executing the playbook the sector rewards with higher multiples and greater institutional interest. Operating Leverage — the condition under which fixed costs are absorbed by growing revenues and incremental sales flow more directly to Earnings — appears to be emerging.

The reaffirmation of full-year revenue guidance at $70 to $73 million is a statement of structural confidence. A company that posts a record quarter and holds its annual outlook is signalling that Q1's performance reflects durable underlying drivers rather than a seasonal aberration. Tuesday's close suggests investors have taken that message fully on board.

This article is for informational purposes only and does not constitute investment advice.